BCM
INDV icon

Bridgeway Capital Management’s Indivior Pharmaceuticals INDV Stock Holding History

Bridgeway Capital Management’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.44M Hold
35,000
– – 0.03% 653
2026
Q1 		$1.07M Sell
35,000
-1,500
-4% -$49.5K 0.02% 694
2025
Q4 		$1.31M Buy
+36,500
New +$1.11M 0.03% 648

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bridgeway Capital Management's INDV Position: Q2 2026 in Review

Bridgeway Capital Management held its Indivior Pharmaceuticals (INDV) position steady in Q2 2026 at 35,000 shares worth $1.44M. The position accounts for 0.03% of the portfolio, ranked #653.

Bridgeway Capital Management first reported a position in INDV in Q4 2025 and has held it in 3 quarters since. 338 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

  • Bridgeway Capital Management held 35,000 shares of Indivior Pharmaceuticals worth $1.44M as of Q2 2026.
  • Bridgeway Capital Management left its Indivior Pharmaceuticals share count unchanged in Q2 2026.
  • Indivior Pharmaceuticals made up 0.03% of Bridgeway Capital Management's portfolio in Q2 2026, its #653 holding.
  • Bridgeway Capital Management first reported a position in Indivior Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 338 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on Bridgeway Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.